-transparent.png){kind=logo}
Aggression is common in dementia, with devastating social consequences. While high or low potency neuroleptics are the usual treatment of choice, they have been shown to yield inconsistent behavioral improvement and significant iatrogenic disability. This double-blind study was undertaken with aggressive demented patients to assess the efficacy and safety of a mid-potency neuroleptic, loxapine, in comparison to the more commonly prescribed high potency drug, haloperidol. Using an optimizing dosage regime, the outcome variables studied were aggression frequency and the number and nature of emergent side effects. Results demonstrated no significant difference regarding efficacy, but significantly fewer side effects with loxapine administration. The clinical and theoretical implications of these findings are discussed.
W Carlyle, and
R J Ancill, and
L Sheldon
October 1977,
Acta psychiatrica Scandinavica,
W Carlyle, and
R J Ancill, and
L Sheldon
April 1984,
The Journal of clinical psychiatry,
W Carlyle, and
R J Ancill, and
L Sheldon
June 1976,
Current therapeutic research, clinical and experimental,
W Carlyle, and
R J Ancill, and
L Sheldon
January 1977,
Current therapeutic research, clinical and experimental,
W Carlyle, and
R J Ancill, and
L Sheldon
August 1974,
Current therapeutic research, clinical and experimental,
W Carlyle, and
R J Ancill, and
L Sheldon
March 1982,
Pharmacopsychiatria,
W Carlyle, and
R J Ancill, and
L Sheldon
April 1976,
Psychopharmacology bulletin,
W Carlyle, and
R J Ancill, and
L Sheldon
January 1978,
Current medical research and opinion,
W Carlyle, and
R J Ancill, and
L Sheldon
July 1975,
Diseases of the nervous system,
W Carlyle, and
R J Ancill, and
L Sheldon
July 1971,
Journal of the American Geriatrics Society,
